John Evans, Beam Therapeutics CEO
Not yet in the clinic, Beam’s base-edited, off-the-shelf CAR-T put on hold
On Friday, the FDA slapped a hold on Beam Therapeutics’ preclinical off-the-shelf CAR-T therapy, the biotech announced this morning.
At the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
